Luye Pharma Group Ltd.

符号: 2186.HK

HKSE

3.02

HKD

今天的市场价格

19.2061
市盈率
1.7660
PEG比率
11.36B
MRK市值
0.00%
DIV收益率

Luye Pharma Group Ltd. (2186-HK) 财务报表

Q: 什么是 Luye Pharma Group Ltd. (2186.HK) 总资产是多少？

Luye Pharma Group Ltd. (2186.HK) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Luye Pharma Group Ltd. (2186.HK). 的默认数据。公司收入显示 2789.84 M 的平均值，即 0.168 % 增长率。整个期间的平均毛利润为 2107.15 M，即 0.187 %. 平均毛利率为 0.771 %. 公司去年的净收入增长率为 -0.119 %，等于 0.338 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Luye Pharma Group Ltd. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.051. 在流动资产领域，2186.HK 的报告货币为10703.282. 这些资产中的很大一部分，即 8522.266 是现金和短期投资。与去年的数据相比，该部分的变化率为0.537%. 公司的长期投资虽然不是其重点，但以报告货币计算的1968.434（如果有的话）为1968.434。这表明与上一报告期相比，-193.448% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 3228.193. 这一数字表明，-0.075% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 12531.185. 这方面的年同比变化率为 0.231%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为2354.899，存货估值为 827.86，商誉估值为 1041.93（如有. 无形资产总额（如果有）按 6317.88 估值. 应付账款和短期债务分别为 767.19 和 5195.75. 债务总额为8423.95，债务净额为 2769.14. 其他流动负债为 2193.37，加上总负债 11962.22. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2011	2009	2007	2005	2003
balance-sheet.row.cash-and-short-term-investments	30442.4	8522.3	5544.3	5510.3	5406.3	5188.1	4862.6	3841.4	2747.4	3206.4	2177.3	343.1	330.5	454.6	320.4	118.5	142.9	95.6	70.4	132.7	54.1
balance-sheet.row.short-term-investments	8899.94	2867.5	3220.5	3072.1	1540.9	2862.6	3189.7	2575.5	2349.6	2362.7	1845.4	10	79	54.5	45.1	0	0	0	0	0	0
balance-sheet.row.net-receivables	9083.1	2354.9	1783.7	1765.1	1553.1	1813	0	0	0	0	0	0	493.4	366.6	355.6	269.5	233.9	169.8	138.3	95.8	72.3
balance-sheet.row.inventory	3262.94	827.9	772.9	746.3	612.3	614.6	585.6	420.4	452.7	285.6	251.2	234.7	105.4	73.3	57.6	56	42.3	33.6	29.1	28.6	16.3
balance-sheet.row.other-current-assets	14658.34	3009.9	4658.7	5059.1	3830.7	3763.4	3227.1	2034.2	2082.4	1579.5	1097.5	1074.5	0.9	0.9	1.7	2.2	46.2	36.3	15.9	5.4	19.4
balance-sheet.row.total-current-assets	47624.65	10703.3	10785.8	10396.7	9970.4	9359.8	8675.3	6295.9	5282.5	5071.4	3526	1652.4	930.2	895.4	735.4	446.3	465.3	335.4	253.8	262.5	162.2
balance-sheet.row.property-plant-equipment-net	19926.44	5127.2	4909.1	4594.5	4339.3	4213.4	3195.6	2463.9	1969.5	1430.8	1320.6	1162.1	669.7	319.4	205	152.4	147.1	106.7	114.9	94.6	99.6
balance-sheet.row.goodwill	4170.88	1041.9	1003.4	985.4	1056.6	1038.1	1040.9	1036.9	995.9	347.4	347.4	347.4	359.4	188.2	188.2	165.9	168.7	44.4	5.9	0	0
balance-sheet.row.intangible-assets	25053.85	6317.9	5984.7	5441.8	4770	4486.9	4445.1	828.7	855.7	126.2	145.9	136.3	406.5	340.5	367.1	200.4	222.1	48	8.7	9.4	10.3
balance-sheet.row.goodwill-and-intangible-assets	29224.74	7359.8	6988.1	6427.2	5826.6	5524.9	5485.9	1865.6	1851.6	473.6	493.2	483.7	765.8	528.7	555.3	366.3	390.8	92.4	14.6	9.4	10.3
balance-sheet.row.long-term-investments	1699.95	1968.4	-2106.4	-2489.9	-1469.4	-2790.8	-3106.1	-2534.7	-2341.1	-2355	-1837.7	-0.3	-72.9	-47	-40.5	0	119.6	9.1	4.5	0.5	0.5
balance-sheet.row.tax-assets	291.01	144.6	113.9	133.1	114.7	93.9	98.4	94.2	93.8	69.4	83.3	79.4	58.5	22.9	21.3	6.9	5.1	1	0.5	0.7	0.2
balance-sheet.row.other-non-current-assets	4815.04	187.4	3559.1	3520.4	1848.9	2912.6	3189.7	2575.5	2349.6	2362.7	2545.4	10.3	103.2	102.8	47.4	94.8	5.5	294.7	4.7	5.4	0.7
balance-sheet.row.total-non-current-assets	55957.17	14787.4	13463.8	12185.4	10660.1	9954.1	8863.5	4464.5	3923.4	1981.5	2604.8	1735.1	1524.2	926.8	788.6	620.5	668	503.8	139.2	110.6	111.3
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	103581.81	25490.7	24249.6	22582.1	20630.6	19313.9	17538.8	10760.4	9205.8	7052.9	6130.8	3387.5	2454.4	1822.2	1524	1066.7	1133.3	839.2	393	373	273.5
balance-sheet.row.account-payables	2864.67	767.2	559.9	570.9	485.3	298.5	279.8	104.6	116.1	83.2	59	69.4	34.3	20.3	13.4	11.7	8.3	9.1	9.8	9.5	12
balance-sheet.row.short-term-debt	25899.19	5195.8	6839.8	5263.2	5642.9	3943.6	5290.5	2861.1	1623.7	502.2	304.9	735.9	453.8	264.1	170.7	65.8	137.3	28.9	10.7	49	88
balance-sheet.row.tax-payables	565.73	294.9	256.3	205.1	358.1	260.2	223.8	249.4	216.5	159.4	122.5	100.4	32	12.3	9.7	3.6	1	0	0	0	0
balance-sheet.row.long-term-debt-total	10671.39	3228.2	2264.7	4227.6	4338.6	4122.3	847.6	0.2	0.4	0.5	0.6	9.4	2	1.3	30	74.9	115.8	0	0	8	37
Deferred Revenue Non Current	264.72	103.6	175	209.4	185.7	131.9	149.6	107.6	147.3	115.2	106.6	78.7	2.5	2.4	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	94.99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	10345.67	2193.4	2087.5	1496.1	1106	17.5	2408.8	57.8	5.4	25.2	37	74.4	28.3	18.8	2.1	57.6	2.8	4.5	20.5	2.6	27.7
balance-sheet.row.total-non-current-liabilities	13045.19	3824.4	3720.7	6138	5297.5	4395.6	1401.9	209.7	269.1	208	205	186.8	159	115	105.4	106.1	142.6	3.5	2.5	11.6	42.6
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	223.17	70.6	38.5	42	24.7	29	0.2	0.4	0.5	0.6	0.1	0.1	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	52136.22	11962.2	13207.9	13468.2	12531.6	9942.1	9604.8	3864.5	2643.8	1253.4	1093.2	1489.8	1050	574	429.2	244.9	356.8	111.1	43.5	89.7	170.4
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1944.43	486.1	457	455.8	418	420.6	421.3	427.3	427.3	427.3	427.3	81.2	81.2	81.2	81.2	81.2	0	0	0	0	0
balance-sheet.row.retained-earnings	14005.23	0	6667.3	6061.8	6209.3	5688.4	0	0	2667.2	1930.9	1206.8	992.1	585.6	460.5	478.1	312.1	14.4	0	0	0	0
balance-sheet.row.accumulated-other-comprehensive-income-loss	16081.52	7885.8	254.5	534	501.5	381.9	-888.7	-735.1	-592.8	-348.2	-290.2	-232.8	-169.6	-145.3	-123.8	-111.2	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	15700.8	4159.3	2797.3	1436.4	762.4	2733.3	8275.8	7076.2	3926.8	3654	3563.8	928.6	780	730	551.8	539.2	761.5	727.6	345	272.1	96.3
balance-sheet.row.total-stockholders-equity	47731.99	12531.2	10176	8488.1	7891.2	9224.2	7808.4	6768.4	6428.5	5664	4907.6	1769	1277.2	1126.4	987.3	821.3	775.9	727.6	345	272.1	96.3
balance-sheet.row.total-liabilities-and-stockholders-equity	103581.81	25490.7	24249.6	22582.1	20630.6	19313.9	17538.8	10760.4	9205.8	7052.9	6130.8	3387.5	2454.4	1822.2	1524	1066.7	1133.3	839.2	393	373	273.5
balance-sheet.row.minority-interest	3713.61	997.3	865.8	625.8	207.8	147.7	125.6	127.5	133.5	135.6	130	128.7	127.2	121.7	107.4	0.6	0.6	0.6	4.5	11.3	6.9
balance-sheet.row.total-equity	51445.6	13528.5	11041.7	9113.9	8099	9371.8	7934	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	103581.81	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	7732.43	1968.4	1114.1	582.2	71.5	71.9	83.6	40.8	8.5	7.7	7.7	9.7	6.1	7.5	4.7	92	119.6	9.1	4.5	0.5	0.5
balance-sheet.row.total-debt	36570.58	8423.9	9104.5	9490.8	9981.5	8065.9	6138.1	2861.4	1624.1	502.7	305.5	745.3	455.8	265.5	200.7	140.8	253.1	28.9	10.7	57	125
balance-sheet.row.net-debt	18731.27	2769.1	6780.8	7052.5	6116.1	5740.4	4465.3	1595.5	1226.3	-341	-26.3	412.2	204.3	-134.7	-74.6	22.3	110.2	-66.6	-59.7	-75.7	70.9

现金流量表

在 Luye Pharma Group Ltd. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.122 的转变。该公司最近通过发行 189.16 扩大了股本，与上一年相比出现了6.380 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 18.77. 公司的投资活动产生了现金使用净额，按报告货币计算达到-1658308000.000. 与上一年相比， -0.517 发生了变化. 在同一时期，公司记录了 671.31, 91.8 和 -8301.9，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 8166.89，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2010	2008	2006	2004
cash-flows.row.net-income	532.61	669.8	-74.6	942.2	1771.7	1473.5	1116.3	974.7	898.1	725.5	383.2	201.1	195.4	166.2	62.1	59	80.9	90.2	71.8	42.6
cash-flows.row.depreciation-and-amortization	331.43	671.3	582	510.9	442	317.2	249.8	140.9	115.2	110.4	100.4	79	70.2	44.8	0	41.2	15.1	11.7	11.1	10.3
cash-flows.row.deferred-income-tax	-914.59	0	-311.9	-505.9	-422.5	-411.5	-317.5	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	20.64	25.4	50	50.9	64.7	31.3	6.3	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	186.15	319.8	-418.1	-300.3	-289.6	-486.2	-113.6	-308.4	-410.2	-375.5	38.1	113	50.9	-13.3	0	5.3	-4.8	-39.8	-38.5	-19.5
cash-flows.row.account-receivables	-403.05	-18.8	-211.8	145	-166.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-30.67	-26.6	-134	4.9	-29	-165.3	32.3	-43.1	-34.4	-16.5	-92	-9.2	-14.5	3.9	0	3.5	-4.5	-0.7	-12.3	-3.3
cash-flows.row.account-payables	118.98	18.8	211.8	-145	166.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	619.86	346.4	-284	-305.2	-260.6	-320.9	-145.9	-265.4	-375.8	-359.1	130.1	122.1	65.4	-17.2	0	1.7	-0.3	-39.1	-26.3	-16.2
cash-flows.row.other-non-cash-items	-381.1	-32.5	355	335.7	178.7	121.3	22.8	-215.2	-208.4	-141.3	-83.1	-68	-62.3	-34.6	43.8	33.1	-40.2	-19.3	3.6	7
cash-flows.row.net-cash-provided-by-operating-activities	689.73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-544.22	-1163.7	-1541.6	-1519.9	-3223	-2484.5	-625.2	-319.1	-208.1	-289.3	-270.9	-338.2	-140.6	-24.5	-44.3	-14	-9.4	-29.4	-11.5	-13.2
cash-flows.row.acquisitions-net	0.11	0	-808.5	-450.8	-2085.1	-1655.2	-5.4	-1674.5	700	-700	2.1	-271.9	-46.2	1.3	0.4	-167.1	0	0	0	0
cash-flows.row.purchases-of-investments	-218.72	-3485.9	-3975.7	-2859.2	-3073.6	-3958.8	-4676.4	-4554	-5919.3	-1840.5	-10	0	0	-45.1	0	0	0	-4	0	0
cash-flows.row.sales-maturities-of-investments	627.68	2899.5	1919	4153.8	3397.3	3326.1	4498.1	4610.6	5655.1	25.9	1	0	0	0.2	0	0	0	0	0	0
cash-flows.row.other-investing-activites	-78.02	91.8	970.7	814.2	2292.8	1774.7	65.2	102.2	12.6	-174.9	-275.5	-33	-4.2	2	40.2	2.7	-335.1	-11.2	-3.6	0.5
cash-flows.row.net-cash-used-for-investing-activites	-78.02	-1658.3	-3436	138.2	-2691.5	-2997.7	-743.7	-1834.9	240.3	-2978.8	-553.4	-643.1	-191.1	-66.2	-3.6	-178.3	-344.4	-44.6	-15.1	-12.7
cash-flows.row.debt-repayment	-561.84	-8301.9	-7536.7	-5896.7	-6739.2	-5943.1	-2629.6	-2282.8	-1294.3	-2187	-1023.9	-448.7	-295.1	-164.7	-203	-161.8	-59	-49	-110	-106.3
cash-flows.row.common-stock-issued	1043.83	189.2	1044.5	7326.7	8828.8	1.6	-281.2	0	0	3139.3	0	0	0	0	0	161.8	320.4	0	104.1	0
cash-flows.row.common-stock-repurchased	0	0	0	-78	-8.8	-21.6	-178.1	0	0	0	0	0	-3.1	0	0	-2	59	0	42	0
cash-flows.row.dividends-paid	0	0	0	-175.5	-376.8	-289.7	-212.6	-107	0	0	0	0	0	0	-14.4	-19.1	-16.5	-14.3	-0.8	-17.4
cash-flows.row.other-financing-activites	1522.95	8166.9	8371.1	-922.6	-97.2	8657.4	4034	3209.8	1345.6	1705.5	1111.2	618.2	359.9	224.6	90.7	108.3	14.6	2.7	10.3	127.4
cash-flows.row.net-cash-used-provided-by-financing-activities	1522.95	54.1	1878.9	254	1606.8	2404.6	732.6	820	51.3	2657.8	87.3	169.5	61.7	59.9	-126.7	87.1	318.6	-60.6	45.6	3.7
cash-flows.row.effect-of-forex-changes-on-cash	14.37	-164.1	-52.4	112.4	-7.5	-45.5	-84.9	-23	5.5	0.6	-3.5	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	3254.94	-114.5	-1427.1	1538	652.6	407	868.1	-445.9	691.8	-1.3	-30.9	-148.6	124.8	156.8	-24.4	47.3	25.2	-62.3	78.5	31.4
cash-flows.row.cash-at-end-of-period	5899.82	2323.7	2438.3	3865.4	2325.4	1672.9	1265.9	397.8	843.7	331.9	333.1	251.5	400.1	275.3	118.5	142.9	95.6	70.4	132.7	54.1
cash-flows.row.cash-at-beginning-of-period	2644.89	2438.3	3865.4	2327.3	1672.9	1265.9	397.8	843.7	151.9	333.1	364	400.1	275.3	118.5	142.9	95.6	70.4	132.7	54.1	22.8
cash-flows.row.operating-cash-flow	689.73	1653.8	182.4	1033.4	1744.9	1045.6	964.1	592	394.7	319.1	438.6	325	254.2	163.2	105.9	138.5	51	42.9	48	40.3
cash-flows.row.capital-expenditure	-544.22	-1163.7	-1541.6	-1519.9	-3223	-2484.5	-625.2	-319.1	-208.1	-289.3	-270.9	-338.2	-140.6	-24.5	-44.3	-14	-9.4	-29.4	-11.5	-13.2
cash-flows.row.free-cash-flow	145.51	490.1	-1359.2	-486.4	-1478.1	-1438.9	338.9	272.9	186.6	29.8	167.7	-13.2	113.6	138.6	61.6	124.5	41.6	13.5	36.5	27.2

利润表行

Luye Pharma Group Ltd. 的收入与上期相比变化了 0.027%。据报告, 2186.HK 的毛利润为 4204.18。该公司的营业费用为 3175.45，与上年相比变化了 -0.351%. 折旧和摊销费用为 671.31，与上一会计期间相比变化了 0.045%. 营业费用报告为 3175.45，显示-0.351% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长-0.270%. 营业收入为 887.44，与上年相比变化了-0.270%. 净利润的变化率为 -0.119%。去年的净收入为532.61.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2011	2009	2007	2005	2003
income-statement-row.row.total-revenue	6143.08	6143.1	5981.7	5200.2	5539.6	6357.6	5173.4	3814.8	2917.8	2563.1	3154.2	2515.1	1774.4	1340.9	954.8	651	509	308.3	344.4	315.4	238.1
income-statement-row.row.cost-of-revenue	1938.9	1938.9	1841.1	1803.5	1549	1478.7	1124	851.5	535	475.7	482.5	413.5	301.1	204.2	136	85.9	80.2	63.5	76.5	105	108
income-statement-row.row.gross-profit	4204.18	4204.2	4140.5	3396.7	3990.6	4878.9	4049.4	2963.4	2382.7	2087.4	2671.7	2101.6	1473.3	1136.6	818.8	565.1	428.8	244.8	267.9	210.4	130.1
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	586.16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	643.97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	2056.17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	0	0.3	-73.3	155.2	-199.9	-121	7.8	3.9	3.1	3.3	0.7	-0.2	126.2	1.1	11.6	13	-10	4.9	-1	-6.3	-6.9
income-statement-row.row.operating-expenses	3038.59	3175.4	3186.6	3113.9	2775.4	3019.2	2532.6	1872.5	1468	1256.5	1946.8	1687.8	1257.9	934.8	656.8	484.2	351.8	164.2	176.5	128.4	72.1
income-statement-row.row.cost-and-expenses	4977.49	5114.4	5027.8	4917.4	4324.4	4497.8	3656.6	2724	2003.1	1732.2	2429.4	2101.3	1559	1139	792.8	570.1	432	227.7	253	233.4	180.1
income-statement-row.row.interest-income	465.49	117.1	88.7	102	110.4	95.9	62.7	27.6	47.7	21.8	25.2	3	4.8	3.8	2.6	3.2	0	0	0	0	0
income-statement-row.row.interest-expense	347.02	675.5	471.8	399.5	424	274.6	170.6	50.4	30.4	15.6	39.5	23.9	19.6	11.3	9.9	14.2	0	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	2056.17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-187.34	-187.3	-545.2	-461.5	-476.8	-218.3	-43.3	25.5	60	67.2	0.6	-30.6	-14.3	-6.5	4.2	1.9	-10	4.9	-1	-6.3	-6.9
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	0	0.3	-73.3	155.2	-199.9	-121	7.8	3.9	3.1	3.3	0.7	-0.2	126.2	1.1	11.6	13	-10	4.9	-1	-6.3	-6.9
income-statement-row.row.total-operating-expenses	-187.34	-187.3	-545.2	-461.5	-476.8	-218.3	-43.3	25.5	60	67.2	0.6	-30.6	-14.3	-6.5	4.2	1.9	-10	4.9	-1	-6.3	-6.9
income-statement-row.row.interest-expense	347.02	675.5	471.8	399.5	424	274.6	170.6	50.4	30.4	15.6	39.5	23.9	19.6	11.3	9.9	14.2	0	0	0	0	0
income-statement-row.row.depreciation-and-amortization	634.89	701.9	671.3	582	510.9	442	317.2	249.8	140.9	115.2	110.4	100.4	79	70.2	44.8	16.1	41.2	15.1	11.7	11.1	10.3
income-statement-row.row.ebitda-caps	1522.33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	887.44	887.4	1215	387	1419	1989.9	1516.8	1090.8	1203.1	1103.6	764.8	406.3	215.4	201.9	162	80.8	77	80.6	91.4	82	58
income-statement-row.row.income-before-tax	700.1	700.1	669.8	-74.6	942.2	1771.7	1473.5	1116.3	974.7	898.1	725.5	383.2	201.1	195.4	166.2	82.8	67	85.5	90.4	75.7	51.1
income-statement-row.row.income-tax-expense	161.02	161	86.5	70.2	238.9	279.8	167.5	135.8	80.7	133.4	111.1	55.2	34.9	45	37	20.7	8	4.6	0.2	-0.5	6.3
income-statement-row.row.net-income	532.61	532.6	604.8	-144.8	706.6	1468.6	1303.4	981.4	891.5	754.5	605.5	310.5	151.6	136.1	123.5	62.1	59	80.9	90.2	71.8	42.6